In some cases, suitability of fucosylated epitopes for cancer management has been utilized, e.g., fucosylated α-fetoprotein has been established as a marker for early detection of hepatocellular carcinoma; fucosylated haptoglobin has been also approved as biomarker for pancreatic and colon cancer [34,35]. This evidence concerns the gene HP and colonic neoplasm.